Comparative evaluation of intratracheal colistimethate sodium, imipenem, and meropenem in BALB/c mice with carbapenem-resistant Acinetobacter baumannii pneumonia

International Journal of Infectious Diseases

Volumn 16, Issue 1, 2012, Pages

  Tang, Hung Jen ^a   Chuang, Yin Ching ^a   Ko, Wen Chien ^b   Chen, Chi Chung ^a,c   Shieh, Jiunn Min ^a,d   Chen, Chung Hua ^e   Lee, Nan Yao ^b   Chiang, Shyh Ren ^a,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^e EN CHU KONG HOSPITAL   (Taiwan)

Author keywords

Carbapenem resistant Acinetobacter baumannii; Colistin; Intratracheal; Meropenem; Mice; Pneumonia

Indexed keywords

CARBAPENEM; CILASTATIN; COLISTIMETHATE; CYTOKINE; IMIPENEM; MEROPENEM; MUCIN;

ACINETOBACTER INFECTION; ANIMAL MODEL; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL STRAIN; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG PENETRATION; DRUG SCREENING; DRUG SENSITIVITY; LUNG; MOUSE; NONHUMAN; PNEUMONIA; SURVIVAL RATE;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ACUTE DISEASE; ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CILASTATIN; COLISTIN; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; IMIPENEM; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; STEM CELLS; THIENAMYCINS;

EID: 84855302139     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2011.09.015     Document Type: Article

References (46)

1. Quinn J.P. Clinical problems posed by multiresistant nonfermenting Gram-negative pathogens. Clin Infect Dis 1998, 27:S117-S124.
2. del Mar Tomas M., Cartelle M., Pertega S., Beceiro A., Llinares P., Canle D., et al. Hospital outbreak caused by a carbapenem-resistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005, 11:540-546.
3. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002, 162:1515-1520.
4. Chastre J. Infections due to Acinetobacter baumannii in the ICU. Semin Respir Crit Care Med 2003, 24:69-78.
5. Sunenshine R.H., Wright M.O., Maragakis L.L., Harris A.D., Song X., Hebden J., et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007, 13:97-103.
6. Garnacho-Montero J., Ortiz-Leyba C., Jiménez-Jiménez F.J., Barrero-Almodóvar A.E., García-Garmendia J.L., Bernabeu-Wittell M., et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003, 36:1111-1118.
7. Corbella X., Montero A., Pujol M., Domínguez M.A., Ayats J., Argerich M.J., et al. Emergence and rapid spread of carbapenem resistance during a large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000, 38:4086-4095.
8. Falagas M.E., Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005, 40:1333-1341.
9. Kallel H., Bahloul M., Hergafi L., Akrout M., Ketata W., Chelly H., et al. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int J Antimicrob Agents 2006, 28:366-369.
10. Markou N., Apostolakos H., Koumoudiou C., Athanasiou M., Koutsoukou A., Alamanos I., Gregorakos L. Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients. Crit Care 2003, 7:R78-R83.
11. Michalopoulos A.S., Tsiodras S., Rellos K., Mentzelopoulos S., Falagas M.E. Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic. Clin Microbiol Infect 2005, 11:115-121.
12. Trottier V., Namias N., Pust D.G., Nuwayhid Z., Manning R., Marttos A.C., et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect 2007, 8:437-443.
13. Levin A.S., Barone A.A., Penço J., Santos M.V., Marinho I.S., Arruda E.A., et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999, 28:1008-1011.
14. Montero A., Ariza J., Corbella X., Doménech A., Cabellos C., Ayats J., et al. Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob Agents Chemother 2002, 46:1946-1952.
15. Kwa A.L., Loh C., Low J.G., Kurup A., Tam V.H. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 2005, 41:754-757.
16. Koomanachai P., Tiengrim S., Kiratisin P., Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007, 11:402-406.
17. Ratjen F., Rietschel E., Kasel D., Schwiertz R., Starke K., Beier H., et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J Antimicrob Chemother 2006, 57:306-311.
18. Rouby J.J., Poète P., Martin de Lassale E., Nicolas M.H., Bodin L., Jarlier V., et al. Prevention of Gram negative nosocomial bronchopneumonia by intratracheal colistin in critically ill patients. Histologic and bacteriologic study. Intensive Care Med 1994, 20:187-192.
19. Korbila I.P., Michalopoulos A., Rafailidis P.I., Nikita D., Samonis G., Falagas M.E. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect 2010, 16:1230-1236.
20. Michalopoulos A., Fotakis D., Virtzili S., Vletsas C., Raftopoulou S., Mastora Z., Falagas M.E. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med 2008, 102:407-412.
21. Czosnowski Q.A., Wood G.C., Magnotti L.J., Croce M.A., Swanson J.M., Boucher B.A., Fabian T.C. Adjunctive aerosolized antibiotics for treatment of ventilator-associated pneumonia. Pharmacotherapy 2009, 29:1054-1060.
22. Ioannidou E., Siempos I.I., Falagas M.E. Administration of antimicrobials via the respiratory tract for the treatment of patients with nosocomial pneumonia: a meta-analysis. J Antimicrob Chemother 2007, 60:1216-1226.
23. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416. American Thoracic Society/Infectious Diseases Society of America.
24. Falagas M.E., Siempos I.I., Rafailidis P.I., Korbila I.P., Ioannidou E., Michalopoulos A. Inhaled colistin as monotherapy for multidrug-resistant Gram (-) nosocomial pneumonia: a case series. Respir Med 2009, 103:707-713.
25. Lu Q., Girardi C., Zhang M., Bouhemad B., Louchahi K., Lu Q.O., et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010, 36:1147-1155.
26. Chiang S.R., Chuang Y.C., Tang H.J., Chen C.C., Chen C.H., Lee N.Y., et al. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 2009, 37:2590-2595.
27. Elman M., Goldstein I., Marquette C.H., Wallet F., Lenaour G., Rouby J.J. Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia. Anesthesiology 2002, 97:199-206. Experimental ICU Study Group.
28. Goldstein I., Wallet F., Nicolas-Robin A., Ferrari F., Marquette C.H., Rouby J.J. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002, 166:1375-1381.
29. Badia J.R., Soy D., Adrover M., Ferrer M., Sarasa M., Alarcón A., et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004, 54:508-514.
30. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 17th Informational supplement. M100-S17. Wayne, PA: Clinical and Laboratory Standards Institute; 2007.
31. Ko W.C., Lee H.C., Chiang S.R., Yan J.J., Wu J.J., Lu C.L., Chuang Y.C. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 2004, 53:393-395.
32. Mimoz O., Jacolot A., Leotard S., Hidri N., Samii K., Nordmann P., Petitjean O. Efficacies of cefepime, ceftazidime, and imipenem alone or in combination with amikacin in rats with experimental pneumonia due to ceftazidime-susceptible or resistant Enterobacter cloacae strains. Antimicrob Agents Chemother 1998, 42:3304-3308.
33. Anhalt J.P. Antimicrobial assays. Laboratory procedures in clinical microbiology. 1985, 691-729. Springer, New York, USA. J.A. Washington (Ed.).
34. Bergen P.J., Li J., Rayner C.R., Nation R.L. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006, 50:1953-1958.
35. Kroeger L.A., Hovde L.B., Mitropoulos I.F., Schafer J., Rotschafer J.C. Colistin methanesulfonate against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2007, 51:3431-3433.
36. Kuo L.C., Yu C.J., Lee L.N., Wang J.L., Wang H.C., Hsueh P.R., Yang P.C. Clinical features of pandrug-resistant Acinetobacter baumannii bacteremia at a university hospital in Taiwan. J Formos Med Assoc 2003, 102:601-606.
37. MacGowan A.P., Bowker K.E., Bedford K.A., Holt H.A., Reeves D.S., Hedges A. The comparative inhibitory and bactericidal activities of meropenem and imipenem against Acinetobacter spp. and Enterobacteriaceae resistant to second generation cephalosporins. J Antimicrob Chemother 1995, 35:333-337.
38. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2002, 6:294-302. Belgian Multicenter Study Group.
39. Rouby J.J., Martin De Lassale E., Poete P., Nicolas M.H., Bodin L., Jarlier V., et al. Nosocomial bronchopneumonia in the critically ill: histologic and bacteriologic aspects. Am Rev Respir Dis 1992, 146:1059-1066.
40. Li J., Milne R.W., Nation R.L., Turnidge J.D., Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma studied by high-performance liquid chromatography. Antimicrob Agents Chemother 2003, 47:1364-1370.
41. Li J., Milne R.W., Nation R.L., Turnidge J.D., Smeaton T.C., Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 2004, 53:837-840.
42. Bressolle F., de la Coussaye J.E., Ayoub R., Fabre D., Gomeni R., Saissi G., et al. Endotracheal and aerosol administrations of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob Agents Chemother 1992, 36:1404-1411.
43. Palmer L.B., Smaldone G.C., Simon S.R., O'Riordan T.G., Cuccia A. Aerosolized antibiotics in mechanically ventilated patients: delivery and response. Crit Care Med 1998, 26:31-39.
44. Goldstein I., Wallet F., Robert J., Becquemin M.H., Marquette C.H., Rouby J.J. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am J Respir Crit Care Med 2002, 165:171-175.
45. Dagan R., Velghe L., Rodda J.L., Klugman K.P. Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges. J Antimicrob Chemother 1994, 34:175-179.
46. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-12.